TheraRadar
Data updated: May 26, 2026

ASTEPRO (azelastine hydrochloride)

Respiratory Approved 2008-10-15

ASTEPRO is indicated for the treatment of Hay Fever; Upper Respiratory Allergy; Nasal Congestion; Runny Nose; Sneezing; Itchy Nose.

Source: FDA Label • Viatris
4
Indications
--
Phase 3 Trials
1
Priority Reviews
17
Years on Market

Details

Status
Discontinued
First Approved
2008-10-15
Patent Cliff
2028

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
NASAL
Dosage Forms
SPRAY, METERED

Companies

Active Ingredient: AZELASTINE HYDROCHLORIDE

ASTEPRO Approval History

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
22 FDA actions from 2008 to 2021 · 2 indication expansions
Jun 2021 SUPPL
Label · Labeling
Sep 2018 SUPPL
Label · Labeling
Sep 2015 SUPPL
Mfg · Manufacturing (CMC)

What ASTEPRO Treats

6 indications

ASTEPRO is approved for 6 conditions since its original approval in 2008. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hay Fever
  • Upper Respiratory Allergy
  • Nasal Congestion
  • Runny Nose
  • Sneezing
  • Itchy Nose
Source: FDA Label

ASTEPRO Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ASTEPRO

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADVAIR DISKUS 500/50
FLUTICASONE PROPIONATE
6 shared
GSK
Shared indications:
Hay FeverUpper Respiratory AllergyNasal Congestion +3 more
FLOVENT DISKUS 100
FLUTICASONE PROPIONATE
6 shared
GSK
Shared indications:
Hay FeverUpper Respiratory AllergyNasal Congestion +3 more
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE
FLUTICASONE PROPIONATE
6 shared
Hikma
Shared indications:
Hay FeverUpper Respiratory AllergyNasal Congestion +3 more
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT05887843 SAN-0791 2023-000362-34 Ph 1 terminated Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis
NCT04729517 HILARIA Aİ-2019-01 Ph 3 completed Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients
NCT00612118 IPR110982 Ph 2 completed A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ASTEPRO FDA Label Details

Indications & Usage

FDA Label (PDF)

ASTEPRO is indicated for the treatment of Hay Fever; Upper Respiratory Allergy; Nasal Congestion; Runny Nose; Sneezing; Itchy Nose.

View full patent landscape →
1 OB patents · 1 families · 65 international docs across 25 countries

ASTEPRO Patents & Exclusivity

Latest Patent: Jun 2028

Patents (1 active)

US8071073 Expires Jun 4, 2028
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for ASTEPRO

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2028
  • 4 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.